Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2019-11-11

2019

Drizou Maria

Κωνσταντίνος Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Παρασκευή Ρούσου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ηλίας Κοττέας, Διδάκτωρ Ιατρικής Σχολής ΕΚΠΑ

Μεταβολές τιμών αιμοπεταλίων και ανταπόκριση-πρόγνωση στην 1ης γραμμής θεραπεία ασθενών με Μη Μικροκυτταρικό Καρκίνο Πνεύμονα

Greek

Platelet count and prognosis-response to 1st line therapy in patients with Non-Small Cell Lung Cancer

Background: The 5-year survival rate for patients diagnosed with lung cancer is below 20% even nowadays. The prognostic role of platelet value hasn’t been fully clarified in this group of patients. The purpose of this study was to investigate the connection between platelet count and the response to 1st line therapy, as well as the prognosis, for advanced non-small cell lung cancer (NSCLC).
Material/Methods: 40 previously untreated patients with stage IV NSCLC were enrolled in this retrospective study and were divided into two equal groups according to their platelet status. Thrombocytosis was defined as platelet counts ≥ 450.000/mm³. We collected clinical parameters and the value of platelets at three different time points: before chemotherapy, at the evaluation of the disease and after progression. The results were correlated with Progression-Free Survival (PFS) and Overall Survival (OS) using univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier analysis.
Results: Patients with normal platelets had a median PFS of 7,8 months, while median PFS was 8,3 months for the group of patients with thrombocytosis. This difference was not statistically significant. Median OS for the two groups was 18,7 and 18,5 months respectively, but there was no statistically significant difference, either. Multivariate survival analyses demonstrated that bone or adrenal metastases were independently associated with disease progression. Finally, adrenal metastases were the only independent prognostic variable.
Conclusions: The present study showed that platelet count cannot be used as a predictive and prognostic marker for our patients. However, further larger studies are needed to evaluate the precise prognostic significance of this parameter for the treatment of NSCLC.

Health Sciences

Non-Small Cell Lung Cancer, Platelets, Thrombocytosis, Response, Prognosis

No

0

Yes

47

68

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2885259